HEART FAILURE
Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression
Victoria Polyakova, PhD*,*,
Stefan Hein, MD ,
Sawa Kostin, MD*,
Tibor Ziegelhoeffer, MD* and
Jutta Schaper, MD*
* Max-Planck-Institute
Kerckhoff-Clinic, Bad Nauheim, Germany
Manuscript received April 13, 2004;
revised manuscript received June 17, 2004,
accepted July 5, 2004.
* Reprint requests and correspondence: Dr. Victoria Polyakova, Max-Planck-Institute, Dept. of Experimental Cardiology, Benekestr. 2, D-61231 Bad Nauheim, Germany (Email: v.polyakova{at}kerckhoff.mpg.de).
OBJECTIVES: We studied the role of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in fibrosis formation in the transition from hypertrophy to heart failure (HF) as well as the cellular source of MMPs and TIMPs.
BACKGROUND: Human pressure-overloaded hearts are characterized by a significant increase in cardiac fibrosis. However, the contribution of the proteolytic/antiproteolytic system in aortic stenosis (AS) during hypertrophy progression has not yet been elucidated.
METHODS: Three groups of AS patients (I: EF >50%, n = 12; II: EF 50% to 30%, n = 10; III: EF <30%, n = 12) undergoing aortic valve replacement and seven controls were studied. Tissue samples were investigated by immunoconfocal microscopy, Western blotting, and zymography.
RESULTS: Quantitative analysis by immunoconfocal microscopy and Western blotting showed an upregulation of MMP-1, -2, -3, -9, -13, and -14 in group I and further increases in later stages. Tissue inhibitors of metalloproteinase-1 and -2 were enhanced and TIMP-4 was decreased in comparison to control. Gelatinolytic activity of MMP-2 significantly (p < 0.05) increased 1.2-fold (group I), 1.5-fold (group II), and 1.6-fold (group III) over control. The level of collagen I was significantly upregulated in all AS groups. Immunoconfocal microscopy showed that MMPs and TIMPs are produced predominantly by fibroblasts. The number of proliferating fibroblasts was significantly elevated during the transition to HF (0.67 n/mm2-control, 5.03-group III, p < 0.05).
CONCLUSIONS: In human hearts a continuous turnover of the extracellular matrix occurs during the progression from compensated hypertrophy to HF that is characterized by the upregulation of MMPs and inadequate inhibition by TIMPs. The altered balance between proteolysis/antiproteolysis with accompanying proliferation of fibroblasts results in fibrosis progression.
|
Abbreviations and Acronyms
| | AS = aortic stenosis | | ECM = extracellular matrix | | EF = ejection fraction | | HF = heart failure | | IHC = immunohistochemical | | LV = left ventricular | | MMP = matrix metalloproteinase | | PBS = phosphate-buffered saline | | TIMP = tissue inhibitor of metalloproteinase | | WB = Western blot |
|
This article has been cited by other articles:
|
|
|
|
 
A. Biolo, S. Ramamurthy, L. H. Connors, C. J. O'Hara, H. K. Meier-Ewert, P. T. Soo Hoo, D. B. Sawyer, D. S. Seldin, and F. Sam
Matrix Metalloproteinases and Their Tissue Inhibitors in Cardiac Amyloidosis: Relationship to Structural, Functional Myocardial Changes and to Light Chain Amyloid Deposition
Circ Heart Fail,
November 1, 2008;
1(4):
249 - 257.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Vinet, P. Rouet-Benzineb, X. Marniquet, N. Pellegrin, L. Mangin, L. Louedec, J.-L. Samuel, and J.-J. Mercadier
Chronic doxycycline exposure accelerates left ventricular hypertrophy and progression to heart failure in mice after thoracic aorta constriction
Am J Physiol Heart Circ Physiol,
July 1, 2008;
295(1):
H352 - H360.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. Paulus, C. Tschope, J. E. Sanderson, C. Rusconi, F. A. Flachskampf, F. E. Rademakers, P. Marino, O. A. Smiseth, G. De Keulenaer, A. F. Leite-Moreira, et al.
How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology
Eur. Heart J.,
October 2, 2007;
28(20):
2539 - 2550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. G. Spinale
Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function
Physiol Rev,
October 1, 2007;
87(4):
1285 - 1342.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. W. Cheng, K. Obata, M. Kuzuya, H. Izawa, K. Nakamura, E. Asai, T. Nagasaka, M. Saka, T. Kimata, A. Noda, et al.
Elastolytic Cathepsin Induction/Activation System Exists in Myocardium and Is Upregulated in Hypertensive Heart Failure
Hypertension,
November 1, 2006;
48(5):
979 - 987.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Roig
Usefulness of neurohormonal markers in the diagnosis and prognosis of heart failure
Eur. Heart J. Suppl.,
September 1, 2006;
8(suppl_E):
E12 - E17.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Aitken, G. Block, A. Lorenzo, D. Herz, N. Sabha, O. Dessouki, F. Fung, M. Szybowska, L. Craig, and D. J. Bagli
Mechanotransduction of Extracellular Signal-Regulated Kinases 1 and 2 Mitogen-Activated Protein Kinase Activity in Smooth Muscle Is Dependent on the Extracellular Matrix and Regulated by Matrix Metalloproteinases
Am. J. Pathol.,
August 1, 2006;
169(2):
459 - 470.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Lopez, A. Gonzalez, R. Querejeta, M. Larman, and J. Diez
Alterations in the Pattern of Collagen Deposition May Contribute to the Deterioration of Systolic Function in Hypertensive Patients With Heart Failure
J. Am. Coll. Cardiol.,
July 4, 2006;
48(1):
89 - 96.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Donal, C. Leclercq, C. Linde, and J.-C. Daubert
Effects of cardiac resynchronization therapy on disease progression in chronic heart failure
Eur. Heart J.,
May 1, 2006;
27(9):
1018 - 1025.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Matsusaka, T. Ide, S. Matsushima, M. Ikeuchi, T. Kubota, K. Sunagawa, S. Kinugawa, and H. Tsutsui
Targeted Deletion of Matrix Metalloproteinase 2 Ameliorates Myocardial Remodeling in Mice With Chronic Pressure Overload
Hypertension,
April 1, 2006;
47(4):
711 - 717.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Manso, L. Elsherif, S.-M. Kang, and R. S. Ross
Integrins, membrane-type matrix metalloproteinases and ADAMs: Potential implications for cardiac remodeling
Cardiovasc Res,
February 15, 2006;
69(3):
574 - 584.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Janssens and H. R. Lijnen
What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models?
Cardiovasc Res,
February 15, 2006;
69(3):
585 - 594.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Janicki, G. L. Brower, J. D. Gardner, M. F. Forman, J. A. Stewart Jr., D. B. Murray, and A. L. Chancey
Cardiac mast cell regulation of matrix metalloproteinase-related ventricular remodeling in chronic pressure or volume overload
Cardiovasc Res,
February 15, 2006;
69(3):
657 - 665.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, P. R. Moreno, Z. A. Fayad, R. Corti, and J. J. Badimon
Atherothrombosis and High-Risk Plaque: Part I: Evolving Concepts
J. Am. Coll. Cardiol.,
September 20, 2005;
46(6):
937 - 954.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Heymans, B. Schroen, P. Vermeersch, H. Milting, F. Gao, A. Kassner, H. Gillijns, P. Herijgers, W. Flameng, P. Carmeliet, et al.
Increased Cardiac Expression of Tissue Inhibitor of Metalloproteinase-1 and Tissue Inhibitor of Metalloproteinase-2 Is Related to Cardiac Fibrosis and Dysfunction in the Chronic Pressure-Overloaded Human Heart
Circulation,
August 23, 2005;
112(8):
1136 - 1144.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Vellaichamy, M. L. Khurana, J. Fink, and K. N. Pandey
Involvement of the NF-{kappa}B/Matrix Metalloproteinase Pathway in Cardiac Fibrosis of Mice Lacking Guanylyl Cyclase/Natriuretic Peptide Receptor A
J. Biol. Chem.,
May 13, 2005;
280(19):
19230 - 19242.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
